Conference Presentation, Panel
Opioid Addiction: A Crisis Fueled by Stigma
Milken InstituteRobert Redfield, Sarah Carlin-Smith, Dr. Kelly Clark, Gary Mendel, Dr. Andrei Ostrovsky, Jerome Adams, Ronnie Solomon, Michael Golinkoff
- Core Thesis: Stigma is identified by the Surgeon General and the panel as the "biggest killer" in the opioid crisis, acting as a primary barrier to treatment, family support, and societal reintegration.
- Definition of Stigma: Dr. Kelly Clark defines stigma as discrimination and prejudice rooted in the failure to view addiction as a chronic brain disease comparable to epilepsy or diabetes.
- Medical Consensus: The panel emphasizes that addiction involves specific brain dysfunction (particularly in the prefrontal cortex), rendering the concept of "voluntary behavior" or "personal fault" scientifically inaccurate and stigmatizing.
- Stigma Hierarchy: Dr. Nora Volkow notes a分化 in public perception, where individuals prescribed opioids are viewed as "no fault," while those with other substance use disorders are unfairly judged as making voluntary, moral choices.
- Economic Reality: Despite 7 of 9 drivers of the opioid epidemic being fueled by stigma, the federal government allocated $0 specifically to attacking stigma in the 2018-2019 budget.
- McKinsey Collaboration: Shatterproof hired McKinsey & Company pro bono to analyze social movements (HIV/AIDS, marriage equality, tobacco) to identify strategies for reducing addiction stigma.
- Key Success Factors: The study identified seven drivers for stigma reduction, including a central coordinating organization, low-cost action items, and a shift from educational facts to humanizing stories.
- Public Opinion Data: Polling reveals 44% of Americans believe addiction is a personal failure (lack of effort), while 80% refuse to associate with an addicted person regardless of the cause.
- Provider Bias: Dr. Andrei Ostrovsky highlights that providers often withhold buprenorphine due to fear of diversion, a reaction driven by broken systems and withdrawal symptoms rather than patient malice.
- X-Waiver Policy: The panel critiques the X-waiver requirement for prescribing buprenorphine as a legacy of stigma that creates logistical barriers, though Dr. Volkow notes the waiver itself is secondary to low reimbursement rates.
- Medicaid Disruption: People currently on Medicaid who enter the criminal justice system lose coverage, creating a critical gap in treatment during the reentry period where overdose risk is highest.
- Treatment Metrics: Dr. Clark states that patients leaving detox without ongoing medication have a higher risk of death within three months than those who never entered the program.
- Employer Strategy: Shatterproof targets the 1,000 largest U.S. companies (employing 30 million people) to pilot "stigma-free" HR policies and return-to-work protocols comparable to chronic disease management.
- Media Framing: Research from the Stigma Lab at Hopkins indicates that stories of recovery reduce stigma, whereas linking recovery to reduced crime rates paradoxically increases stigma.
- Funding Disparity: The National Institute on Drug Abuse (NIDA) receives ~$1.4 billion annually, significantly less than the NIH's funding for cancer ($7.25 billion) or heart disease, despite higher prevalence of substance use disorders.
- Treatment Gaps: 60% of U.S. treatment facilities do not utilize FDA-approved medications for opioid use disorder (MOUD), and only 2% offer all three types (methadone, buprenorphine, naltrexone).
- Settlement Allocation: Drug company settlement funds face a two-step hurdle: ensuring money is not absorbed into general state budgets (e.g., fixing potholes) and ensuring it is spent on evidence-based programming.
- Oklahoma Precedent: In the $260 million Oklahoma settlement, $175 million was directed to a foundation for substance use disorder, serving as a model for how settlements can be structured to mandate addiction-specific spending.
- Implementation Science: NIDA is funding four states (MA, OH, NY, KY) to demonstrate that integrated, evidence-based interventions can reduce overdose mortality by 50% within 1.5 years.
- Privacy Laws: Dr. Clark and Dr. Volkow advocate for removing 42 CFR Part 2 restrictions that separate addiction records from general medical records, arguing such separation institutionalizes stigma.
- Recovery vs. Treatment: Dr. Volkow distinguishes between clinical treatment and "recovery," noting that recovery requires rebuilding social structures that are often destroyed by the disease and stigma.
- Human Element: The panel stresses that policy discussions must move beyond statistics to address the emotional reality of families losing children to overdose.